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Abstract
Objective: UTUCC is a rare tumor and most reports on prognostic factors come from 
small single centers series. The objective of this article was to provide an updated 
overview of current clinical, pathological and biological prognostic factors of UTUC. 
Methods: PubMed was searched for records from 2002 to 2010 using the terms 
“prognostic factors”, “recurrence”, “survival”, and “upper tract urothelial carcinoma”. 
Among identified citations, papers were selected based on their clinical relevance.
Results: Classical  clinical  factors  that  influence  UTUC  prognosis  include  age, 
presence  of  symptoms,  hydronephrosis  and  interval  from  diagnosis.  Many 
biomarkers have shown promises to  better  appraise the natural  course of  UTUC 
although  none  is  currently  used  in  clinical  practice.  Stage,  grade,  lymph  node 
metastases,  lymphovascular  invasion,  tumor necrosis,  and tumor  architecture  are 
strong pathological parameters. RNU is the standard treatment of localized UTUC. 
Both laparoscopic and open approaches seem to offer similar cancer control. Lymph 
node dissection increases staging accuracy and might confer a survival benefit. 
Conclusion: RNU  is the standard treatment for most patients with UTUC. Recent 
multicenter  studies  confirmed  the  prognostic  value  of  classical  prognostic 
parameters.  Better  survival  prediction  might  be  obtained with  prognostic  systems 
including clinical data and new biomarkers.
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Introduction
Upper tract urothelial carcinoma (UTUC) is a rare tumor that represents 5% of 
all genitourinary malignancies.[1] It occurs more frequently in the renal pelvis than in 
the ureter with a ratio of 3:1.[2, 3] Classical risk factors for the development of UTUC 
include smoking, abuse of analgesics, chronic urinary tract infection, stone disease, 
and oncologic agents such as cyclophosphamide.[2] UTUC can develop after primary 
bladder cancer in up to 10% of cases. Secondary bladder cancer after primary UTUC 
is more common with a risk of 20 to 50%.[3-5]
Radical nephro-ureterectomy (RNU) with ipsilateral bladder cuff excision is the 
surgical standard of care for patients with non metastatic UTUC. Despite effective 
local  therapy,  disease  recurrence  and  progression  remain  common. The  most 
important  prognostic  factor  of  UTUC  is  disease  stage.  Five-year  survival  rates 
approach 90% for low stage tumors and decrease to < 30% in cases of regional 
nodal  metastases  and  <  10%  in  case  of  distant  metastases.[5] Endoscopic 
management can be an option for patients with small, unilateral low stage and low 
grade tumors [6, 7].
Because of the rarity of  UTUC, most of  the publications concerning UTUC 
were  single  center  series,  until  recently.  Although  they largely  contributed  to  the 
understanding of the disease, they were limited by small size and heterogeneous 
populations. To overcome this limitation and in an effort  to better understand the 
natural  history,  a  comprehensive  database  (UTUCC;  the  Upper  Tract  Urothelial 
Carcinoma  Collaboration)  incorporating  the  clinico-pathologic  characteristics  and 
outcomes of more than 1300 patients treated with RNU for UTUC at 13 academic 
centers worldwide was created in 2008.[8] Many publications focusing on prognostic 
3
factors came out of  this  collaborative effort.  To externally validate the findings of 
these studies, a validation cohort based on over 700 RNU cases was created.
In the light of data, the objective of this review was to investigate prognostic 
factors of UTUC outcomes.
Clinical factors
Age. There is very limited data on the impact of age on clinical outcomes in UTUC. In  
a retrospective study from the UTUCC including 1453 patients, Shariat et al. reported 
that older age was an independent predictor of cancer-specific mortality (CSM).[9]  
This finding could be explained by a change in the biological potential tumor cells, a 
decrease  in  the  host's  defense  mechanisms,  or  differences  in  care  patterns.[10] 
However, advanced age alone should not be an exclusion criterion for the aggressive 
treatment of potentially curable UTUC. A large proportion of elderly patients can be 
cured with RNU.[9] Therefore, chronological age alone is an inadequate indicator of 
outcomes in  older  UTUC patients  and should  not  be  used  to  deny a  potentially 
curative intervention to elderly patients.[9]
Gender. No difference has been shown in histopathological features and outcomes 
between men and women treated with RNU for UTUC.[11, 12]
Symptoms. The presence of symptoms is a classical prognostic factor in renal cell 
carcinoma (RCC) patients.[13] The UTUCC studied 654 patients managed by RNU 
and found no difference in terms of recurrence-free survival between patients with 
incidental tumors and patients with local symptoms. However, patients with systemic 
symptoms  had  a  significantly  higher  risk  of  disease  recurrence  (p<0.001).[14] 
Nevertheless, systemic symptoms could not predict recurrence or cancer death in 
multivariable  analysis.  Yet,  symptom  classification  improved  the  accuracy  of  a 
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predictive model comprising stage, grade and lymph node status. In a smaller series 
of 168 patients, Inman and colleagues built a preoperative model, where presence of 
constitutional  symptoms  (pain  or  weight  loss)  was  a  predictor  of  overall  survival 
(p=0.007), and trended towards predicting cancer mortality (p=0.064).[15] 
Hydronephrosis. In bladder cancer, hydronephrosis is a sign of advanced disease 
and a predictor of poor outcome.[16] In UTUC, two previous studies reported that  
non-visualization  of  the  urinary  tract,  delayed  excretion,  or  hydronephrosis  were 
associated with invasive ureteral cancer.[17, 18] 
Interval  from  diagnosis.  As  suggested  in  bladder  cancer[19],  a  recent  study 
showed that longer interval from diagnosis of UTUC to RNU was associated with 
aggressive features, such as more advanced stage and higher tumor grade, but not  
with  disease recurrence or cancer-specific mortality.  However,  in the subgroup of 
patients with stage ≥ pT2, longer delay was associated with higher risk of disease 
recurrence and cancer-specific mortality.[20]
Biomarkers
Conventional serum markers. Recent research into the profiling of UTUC at the 
molecular level has begun to shed light on important mechanisms of pathogenesis, 
as  well  as  providing  a  number  of  potential  diagnostic  and  prognostic  markers.  
Molecular markers have the potential to be used clinically to screen for, diagnose, or 
monitor the activity of diseases and to guide molecular targeted therapy or assess 
therapeutic response. The prognostic value of proteins implicated in the regulation of 
cell cycle (p53 and p27), apoptosis (bcl2, survivin), cell adhesion (E-Cadherin) and 
cell proliferation (Ki67) have been suggested in small single-center series.[3, 21, 22] 
E-Cadherin  and Ki67 were  shown to  be independent  prognostic  factors  of  tumor 
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recurrence in multivariable analysis.[21, 22] Microsatellite instability has also been 
identified as an independent prognostic parameter, mainly among patients with pT2-
T3 N0 M0 UTUC.[3, 23] Although these markers are promising, none are used in 
clinical  practice.  Tissue  microarray  studies  are  currently  ongoing  as  part  of  the 
UTUCC  biomarker  and  validation  project.  Based  on  the  lower  tract  urothelial 
carcinoma  experience,  a  combination  of  complementary  and  yet  independent 
molecular markers will likely better capture the biologic potential of each individual 
urothelial tumor, resulting in improved clinical decision-making.
Laparoscopic versus open RNU
There has been a controversy regarding the laparoscopic treatment of UTUC 
because of the fear of potential tumor seeding. Most of the studies are retrospective 
and it is unlikely that a large randomized analysis will be performed due to the rarity 
of UTUC. However, the retrospective series suggest that the laparoscopic approach 
is safe and effective in appropriately selected patients.
While some authors reported a higher risk of intravesical disease recurrence 
with  laparoscopic  approach  [24],  the  studies  were  small,  monocentric  and 
multivariable analyses failed to characterize treatment modality as an independent 
risk  factor  for  disease  recurrence.[25,  26]  A  recent  publication  from the  UTUCC 
including 1249 patients reported that laparoscopic RNU offered equivalent oncologic 
efficacy to open surgery in selected patients. There was no difference between the 
two  approaches  with  respect  to  disease  recurrence  or  cancer-specific  mortality; 
although patients treated laparoscopically  had significantly  more favorable cancer 
characteristics which might have resulted in selection biases.[27] Other retrospective 
reports confirmed these findings.[27-29] There is only one prospective randomized 
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study that included 80 patients treated with either laparoscopic or open RNU. With a 
follow-up of 44 months, the authors found comparable oncologic outcomes between 
the laparoscopic and open group.  However,  in  patients with  pT3 and high grade 
UTUC, there was a slight advantage in cancer specific survival in favor of the open 
RNU.[30]  Results  were  comparable  with  the  retroperitoneal  approach,  with  low 
complications rate suggesting that it was also a safe procedure.[31, 32] 
Endoscopic treatment
Endoscopic surgery can be considered in imperative situations (solitary kidney, 
bilateral disease, significant comorbidities) but also in selected patients with a small 
low grade tumor. Both retrograde and antegrade approaches can be used depending 
on tumor volume and location.[7] Retrograde uretersocopy has a low morbidity but 
requires smaller instruments that limit the size of the tumor that can be treated.[6] In 
addition, some portions of the upper urinary tract, such as the lower pole calyces,  
can sometimes not  be  reliably  reached with  working  instruments.  The antegrade 
approach allows the treatment of larger tumors but with the potential risk of tumor  
seeding.  Only  limited  monocentric  series  report  on  the  endoscopic  treatment  of 
UTUC with a recurrence risk of about 30%.[6, 7]
Adjuvant instillations
Because  of  the  high  local  recurrence  rate  of  patients  managed  endoscopically 
(around 30%), adjuvant topical chemotherapy has been utilized. The instillation can 
be accomplished via a nephrostomy tube or through a ureteral catheter. The same 
agents used to treat urothelial carcinoma of the bladder are used to treat tumors of  
the  upper  tracts  (i.e.,  BCG,  mitomycin  and  other  chemotherapies).  Although  the 
7
cumulative  experience  appears  encouraging,  no  long-term  study  has  shown 
statistical improvement with relation to survival and recurrence rates.[33, 34]   This 
may be due to  insufficient numbers to show clinical significance, given the relative 
rarity of the disease, differential biology of upper urinary tract versus bladder tumors, 
or inadequate delivery systems that do not allow for uniform delivery and adequate 
dwell times to enable a clinical response.
Pathological factors
Tumor  location.  Historically,  the  prognostic  impact  of  tumor  location  resulted  in 
contradictory results. Tumors within the renal pelvis are more common than ureteral 
lesions,  but  small  single-institution  series  have  suggested  that  ureteral  disease 
confers worse prognosis.[35] A European study, including 269 patients from three 
academic centers who underwent RNU at three academic centers, noted that tumor 
location was not independently associated with clinical outcomes.[36] A larger series 
from the UTUCC showed that in 1249 patients that there is no difference in terms of 
recurrence  or  cancer-specific  mortality  between  ureteral  and  renal  pelvic  tumors 
(p=0.133).[37] This was confirmed in nine SEER registries relying on 2824 patients; 
Isbarn et al.  failed to  detect an association of tumor location with  cancer-specific 
survival.[38] Finally, Favaretto et al. confirmed the lack of prognostic importance of 
tumor location when adjusted for the effects of standard pathologic variables in RNU 
patients.[28]
Tumor architecture.  Tumor architecture (infiltrative or papillary)  was found to be 
associated with disease recurrence in international multicenter analyses.[8, 39, 40] 
Five years after RNU, 40% of patients with papillary vs. 77% with infiltrative tumors 
had  disease  recurrence.[39]  Langner  at  al.  showed  that  infiltrative  pattern  was 
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significantly  associated  with  the  development  of  metastatic  disease  and  was  an 
independent  prognostic  factor  of  survival.[41]  Combining  this  parameter  with 
histological  grade and tumor  location  in  1453 patients,  a  preoperative  prognostic 
model achieved 76.6% accuracy in predicting non-organ confined UTUC.[40]
Tumor stage. Tumor stage is currently the most important prognostic indicator of 
UTUC.  Upper tract  urothelial  carcinomas can spread by direct  invasion,  mucosal 
seeding, hematologic and lymphatic routes. The metastatic potential, and therefore 
the prognosis, worsens with advancing tumor stage.  All the largest series validated 
tumor stage as a prognostic indicator.[3, 5, 8] Patients with pTa-pT1 tumors have a 
5-year cancer-specific survival > 90%, whereas patients with pT3-4 tumors have a 5-
year cancer-specific survival of 40.5% and 19% respectively.[4, 36] Tumor stage is 
also associated with a higher risk of local recurrence in many studies.[8, 42-44] In the  
UTUC  studies,  advanced  pathological  stage  was  consistently  associated  with 
disease recurrence and cancer specific survival.[8, 45, 46] 
Lymph node invasion. Up to 30% of patients with muscle-invasive UTUC present 
with  lymph  node  (LN)  metastasis  at  diagnosis,  which  is  associated  with  poor 
prognosis.[2, 3] Lymph node invasion has been demonstrated to be one of the most 
important predictors of poor outcome in patients treated with RNU.[8, 36, 40, 43, 47] 
There are no definitive data supporting the survival benefit of lymph node dissection 
in UTUC patients. Indications for lymphadenectomy are extrapolated from bladder 
cancer data that advocate extensive pelvic lymph node dissection to improve both 
staging  and  survival  in  patients  undergoing  radical  cystectomy.[48]  In  a  study 
comprising 1130 patients from the UTUCC, 5 year  specific survival  was lower  in 
patients  with  pN+  disease  compared  to  those  with  pNx  disease  (35% vs.  69%, 
p<0.001).[47, 49, 50] Interestingly, patients with pNx disease had a worse prognosis  
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than pN0 patients,  particularly  in  patients  with  advanced T stage.  Therefore,  the 
authors recommend that patients suspected to have pT2-T4 disease should undergo 
lymphadenectomy to  improve  staging  and  eventually  help  guide  decision-making 
regarding  adjuvant  chemotherapy.  Based  on  patients  from the  same  cohort,  the 
authors further studied the importance of the extent of lymphadenectomy. [47, 49, 50] 
In the entire population, the number of LNs removed was not associated with cancer 
mortality.  However,  in the subgroup of pT0 patients, the extension of lymph node 
dissection  seemed  to  be  associated  with  better  cancer-specific  survival.[50]  A 
minimum of 8 LNs seemed to be the most informative cut-off with 75% probability of 
detecting  one  or  more  positive  LN,  and  accurate  prediction  of  cancer-specific 
mortality.[49,  50]  Finally,  Bolenz  et  al.  demonstrated  that  LN  density  (using  a 
threshold of 30%) significantly affected cancer-specific mortality in UTUC patients.
[51]
Lymphovascular  invasion  (LVI).  LVI  has  been  shown  to  have  an  important 
prognostic role, and assessment of this feature may help identify patients who could 
benefit from multimodal therapy after  RNU.[43, 52] Lymphatic vessels serve as the 
primary pathway for metastatic tumor cell spread in many types of cancer.[53] Early 
studies reported that LVI is an independent prognostic factor in UTUC.[43, 54, 55] 
More  recently,  the  UTUCC  confirmed  that  patients  with  LVI  had  worse  cancer-
specific  survival  than their  counterparts  without  LVI.[56]  LVI  was  an independent 
predictor  of  both  disease  recurrence  and  cancer-specific  mortality,  even  among 
patients  who  had  either  negative  lymph  nodes  or  who  did  not  undergo 
lymphadenectomy [56]. LVI  was associated with established features of biologically 
aggressive UTUC, such as advanced stage, high tumor grade, metastasis to lymph 
nodes, infiltrative tumor architecture, tumor necrosis, and concomitant carcinoma in 
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situ (CIS).[36, 57] In addition, lymphovascular invasion was an independent predictor 
of  both  disease  recurrence  and  cancer-specific  mortality.  When  evaluated  in  all 
patients,  addition of  LVI to  standard pathologic  features improved their  predictive 
accuracy for both disease recurrence and cancer-specific mortality by a statistically 
significant  but  clinically  small  margin.  This  margin  was  significantly  larger  and 
clinically significant when the analyses were restricted to patients without lymph node 
metastasis and those who did not undergo a lymphadenectomy. Besides inclusion in 
predictive tools for selecting adjuvant therapy, LVI could be considered for inclusion 
in the TNM staging system such as in hepatic and testicular cancer.  However,  a 
limitation  is  the  inherent  difficulty  in  determining  the  presence  of  LVI  at  the 
morphological  level,  with  significant  differences  between  pathologists.  Retraction 
artifacts of the surrounding stromal tissue can mimic vascular invasion. Therefore, 
experts have recommended reporting LVI only in unequivocal cases, and to make 
use of immunohistochemistry, if necessary. The use of immunohistochemical staining 
to identify the vessels remains controversial and not practical for everyday clinical  
use.  It is of utmost importance that strict morphological criteria are established to 
standardize and make the diagnosis of LVI reproducible, and consequently allow its 
recommendation in daily clinical setting.[43] 
Tumor grade.  Tumor grade is currently divided into papillary urothelial neoplasia of 
low  malignant  potential,  low-grade  carcinomas  and  high-grade  carcinomas.  Until 
2004,  the most  common classification used was the WHO classification of  1973, 
which  distinguished three grades (G1,  G2,  G3).[58] High-grade tumors  are  more 
likely to invade the underlying connective tissue, muscle, and surrounding tissues 
and  are  also  more  likely  to  be  associated  with  concomitant  CIS.[16,  51]  The 
prognostic role of pathological grade is controversial. Several authors did not find any 
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prognostic role for tumor grade [36, 52, 59], whereas others reported an effect of 
grade on UTUC recurrence and/or progression.[42, 44] These discrepancies might 
be related to similarities between grade 1 and 2 tumors and to the well-known intra- 
and interobserver variability to assign grade.  Most recent series, including the one 
from UTUCC, used a 2-tiered grading system and found that high tumor grade was a 
strong independent prognostic factor in patients treated with RNU.[8, 39, 40] 
Tumor necrosis. Only a few reports have addressed the prognostic value of tumor 
necrosis in UTUC. Langner et al. showed that tumor necrosis was an independent 
predictor of  clinical  outcomes and could predict  distant metastasis after  RNU.[60] 
This was subsequently confirmed by Simone [61] and by two large UTUCC series.
[62, 63] In multivariable analyses, tumor necrosis was an independent predictor of 
both  disease  recurrence  and  cancer-specific  mortality.[62]  Assessment  of  tumor 
necrosis may help to identify patients who could benefit  from multimodal therapy.  
Therefore, evaluation of extensive tumor necrosis has been suggested to become 
part  of  standard  pathologic  reporting.[62]  Further  extended  validation  is  needed 
before tumor necrosis can be used to guide clinical decision-making after RNU.
Carcinoma in situ (CIS). Carcinoma in situ is a cytological lesion of the urothelium 
and the basal membrane, with pre-invasive and invasive potential. In bladder cancer, 
CIS is associated with an increased risk of disease recurrence and progression.[64] 
In a series including 79 patients, CIS was a significant independent parameter of 
subsequent bladder recurrence (p=0.005).[65] The UTUCC confirmed these findings 
in 1387 patients; the presence of concomitant CIS in patients with organ confined 
UTUC  (≤  pT2  N0M0)  was  associated  with  worse  outcomes  and  a  significantly 
increased risk of both cancer recurrence and cancer-specific mortality.[66-68]
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Conclusion
Radical nephroureterectomy is the standard treatment for most patients with UTUC. 
Both laparoscopic and open approaches offer similar cancer control in appropriately 
selected  patients.  Lymphadenectomy seems to  offer  both  a  staging  and  survival 
benefit.  The recent  worldwide collaborative efforts confirmed classical  clinical  and 
pathological prognostic parameters (i.e. stage, grade, lymph node metastases) and 
new ones (LVI, necrosis, architecture). To better appraise the course of UTUC, there 
is a need to identify new biomarkers that could serve as prognostic indicators to 
include patients into clinical trials or help guide the clinical decision making regarding 
the type of treatment, integration of multimodal treatment and, response to treatment. 
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